Low-dose CDB 4124 (at doses of 1, 3, 6, 9 and 12mg) for the treatment of uterine leiomyoma and endometriosis

Trial Profile

Low-dose CDB 4124 (at doses of 1, 3, 6, 9 and 12mg) for the treatment of uterine leiomyoma and endometriosis

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2013

At a glance

  • Drugs Telapristone (Primary)
  • Indications Endometriosis; Uterine leiomyoma
  • Focus Adverse reactions
  • Sponsors Repros Therapeutics
  • Most Recent Events

    • 17 Dec 2010 Planned number of patients changed to 60. According to a Repros Therapeutics media release, there will be 12 patients per dose cohort.
    • 17 Dec 2010 Status changed from not yet recruiting to recruiting. According to a Repros media release, patients in the 1mg dose cohort have completed 8 weeks of treatment, and dosing of the 3mg dose cohort will commence soon.
    • 27 Jul 2010 The Investigational Review Board approved the trial. Dosing of the first patient expected in the quarter 3 of 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top